Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (145)	11/26/2001 7:30:21 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 447

<<This acquisition, together with OSI's established expertise in drug discovery, provides OSI with a team of over 350 research and development professionals comprising a comprehensive array of capabilities and expertise in small molecule drug discovery and development, principally in the oncology area.>> This is huge. Who will pay for this efforts? Certainly, they will need revenue from Tarceva, before cash reserve evaporate. Miljenko